Integrative Medicine

Yes, it is possible. This is a major advantage of amniotic fluid injection. Anticoagulants are usually discontinued before PRP therapy to avoid affecting platelet function or causing bruising. However, amniotic fluid injection does not require drawing blood from the patient’s own body. Therefore, patients taking anticoagulants, those with anemia, or those with poor vascular conditions can safely receive this treatment without the risk of discontinuing medication.

Amniotic membrane injection has a dual effect of “anti-inflammatory” and “tissue repair.” Short-term (1-2 weeks): Due to the anti-inflammatory effect, many patients experience significant pain relief. Long-term (3-6 months): This is a critical period for tissue regeneration, and function will continue to improve. Unlike PRP, which usually requires 3-6 treatments, amniotic growth factor, due to its high concentration and long-lasting efficacy, allows most patients to see results with only one treatment; if the condition is severe, a second booster treatment can be administered after 3 months, subject to physician evaluation.

It’s definitely worth trying. The effectiveness of PRP is highly dependent on the patient’s own blood quality. If you are older, have chronic diseases, or have insufficient blood growth factor concentration, the repair capacity of PRP may be limited. In contrast, amniotic growth factor is a “standardized high-concentration formulation” that is not affected by the patient’s constitution and additionally contains the “extracellular matrix (ECM)” scaffold that PRP lacks, providing a more stable repair environment for tissues. It is particularly suitable for patients with intractable pain who do not respond to PRP treatment.

The risk is extremely low. Amniotic membrane tissue possesses a unique ****immune-privileged** characteristic, meaning it is unlikely to trigger an immune rejection response in the human body (which is why the fetus is not rejected in the womb). Furthermore, amniotic membrane preparations used in reputable medical institutions (such as Amniofix®) are derived from healthy donors delivered via cesarean section and undergo rigorous screening and patented aseptic processes in accordance with US FDA and AATB (American Association of Tissue Banks) standards, ensuring their safety has been widely validated internationally.